Cover Image
Market Research Report
Product code
1020359

Global Frozen Shoulder Syndrome Market - 2021-2028

Published: | DataM Intelligence | 180 Pages | Delivery time: 2 business days

Price

Back to Top
Global Frozen Shoulder Syndrome Market - 2021-2028
Published: July 28, 2021
DataM Intelligence
Content info: 180 Pages
Delivery time: 2 business days
  • ALL
  • Description
  • Table of Contents
Description

Frozen Shoulder Syndrome Market. Overview

The frozen shoulder syndrome market. The size was valued at US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Frozen shoulder is also known as adhesive capsulitis. It is characterized by stiffness and pain in the shoulder joint. Signs and symptoms typically begin gradually, worsen over time, and resolve, usually within one to three years.

Frozen Shoulder Syndrome Market. Dynamics

The increased incidences of frozen shoulder will drive the market. And the high prevalence of diabetes and cardiovascular diseases may increase the risk of developing frozen shoulder.

The increased incidences of frozen shoulder will drive the market

The prevalence rate of frozen shoulder is estimated to be 2 to 5 percent of the general population. Frozen shoulder syndrome (FSS) usually affects patients aged 40-60 years. The incidence of FSS is not precisely known; however, it is estimated that 2% to 5% of the general population develops the disease over their lifetime. Men tend to be affected less frequently than women, and there is no preference for race. In general, bilateral shoulder involvement is rarely simultaneous and instead occurs sequentially.

Around 70% of individuals who suffer with a frozen shoulder are females. Among individuals 35-65 years old, with an occurrence rate of approximately 2-5% in the general population, In China and Japan, it's called the 50-year-old shoulder due to its prevalence at that age.

The high prevalence of diabetes and cardiovascular diseases may increase the risk of developing frozen shoulder

The musculoskeletal system can be affected in different ways by diabetes. The shoulder is one of the frequently affected sites of the body. Frozen shoulder (adhesive capsulitis) is one of the rheumatic conditions caused by diabetes. It is characterized by pain and severe limited active and passive range of motion of the glenohumeral joint, mainly external rotation. People with other health conditions, including heart disease, lung disease, chronic bronchitis, and diabetes, may have an increased risk of developing frozen shoulder. Cardiovascular disease, Parkinson's disease, and an overactive thyroid gland (hyperthyroidism) are also linked to this condition

The global diabetes prevalence in 2019 is estimated to be 9.3% (463 million people), rising to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045. The prevalence is higher in urban (10.8%) than rural (7.2%) areas and in high-income (10.4%) than low-income countries (4.0%).

Cardiovascular diseases (CVDs) are one of the leading cause of death globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. Moreover, over three-quarters of CVD deaths take place in low- and middle-income countries. Hence, with the rise in the incidence of these diseases, the frozen shoulder syndrome market will see a increase in the forecast period.

High treatment cost will hamper the market

Management of frozen shoulder is non-surgical, ranging from supervised neglect to joint distension, or surgical treatment in the form of manipulation under anesthesia (MUA), arthroscopic arthrolysis, or open capsular release. Non-surgical treatment is the first-line approach in most cases, followed by surgical intervention in those who fail to respond. There is limited high-quality evidence to support one treatment over another, be it surgical or non-surgical, with even less data on rates of surgery and cost-effectiveness. The cost of various non-surgical treatments may vary, with the surgical intervention being the highest.

Most of the treatments involve controlling shoulder pain and preserving as much range of motion in the shoulder as possible. OTC ( over-the-counter)pain relievers, such as aspirin and ibuprofen (Advil, Motrin IB, others), may help to reduce pain, inflammation associated with frozen shoulder. In some cases, a doctor may prescribe stronger pain-relieving and anti-inflammatory drugs.

A physical therapist can teach range-of-motion exercises to help recover as much mobility in the shoulder as possible. The commitment to doing these exercises is essential to optimize recovery of mobility

COVID-19 Impact Analysis

COVID-19 has affected the healthcare industry. To curb its growth, government-imposed lockdown, which led to a huge impact on every sector, including the frozen shoulder syndrome market. In addition, the treatment was delayed due to the high demand for COVID-19 treatment in the hospitals.

Frozen Shoulder Syndrome Market. Segment Analysis

The physical Therapy type segment will dominate the market

The two major goals of frozen shoulder syndrome treatment are to increase motion and decrease pain. Much physical therapy and home exercises can be used as a first-line treatment for adhesive capsulitis. Physical therapy has shown to bring about pain relief and return of functional motion. When used in Medication with physical therapy, NSAIDs were proven to be more effective than using NSAIDs alone. Similarly, various studies on intra-articular corticosteroids used in Medication with physiotherapy resulted in better outcomes than intra-articular corticosteroids alone. Physical therapy for frozen shoulder involves using therapeutic modalities and procedures to decrease the pain and aggressive range of motion (ROM) exercises to help improve shoulder's mobility. PT should teach what to expect from treatment for frozen shoulder, and they should guide things that one can do to help ones condition.

In more than 90% of cases, frozen shoulder goes away with physical therapy and time. But, even when physical therapy is done consistently, it may still take up a year to gain back all lost shoulder function.

Hospitals will dominate the market

Hospitals have been seeing a growth in the market due to the presence of advanced medical equipmets. Structured physiotherapy for the treatment of frozen shoulder, is provided at low cost, is as effective as the other options available , and many people value the shorter waiting times. The availability of such treatments in hospitals as well as better facilities for physical therapies and staff to give better treatment will see a rise in the hospital segment of frozen shoulder syndrome market.

Frozen Shoulder Syndrome Market. Geographical Analysis

North America will dominate the frozen shoulder syndrome market

Due to an increase in R&D and technologically advanced products introduced in the market, this region will see a rise in its demand.

According to the American Academy of Orthopaedic Surgery, frozen shoulder incidences occur in 2% of the general population. Risk factors for frozen shoulder are both age and gender. Those between the ages of 40 and 60 are more likely to get frozen shoulder. It's also more common in women.

In Washington D.C [USA], on June 21st, a team of scientists developed a minimally invasive treatment that quickly reduces pain due to decreased errant blood flow to the shoulder and improves function in patients with adhesive capsulitis, also known as frozen shoulder.

Frozen Shoulder Syndrome Market. Competitive Landscape

The major players covered in the frozen shoulder syndrome market are GlaxoSmithKline plc, Contract Pharmacal Corp, Amneal Pharmaceuticals, Inc., Vintage Pharma, Dr. Reddy's Laboratories Ltd, Marksans Pharma, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Perrigo Company plc, Johnson & Johnson Services, Inc, .), Shanghai Pharmaceutical Group Co., Ltd., China Resources Pharmaceutical GroupCo., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.

Frozen Shoulder Syndrome Market. Key Companies to Watch

GlaxoSmithKline plc

Overview: GlaxoSmithKline plc is a multinational British pharmaceutical company which has its headquarters in Brentford, England. Its is a science-led global healthcare company with a particular purpose: to help people do more, feel better, live longer. They have three global businesses that do research, develop and manufacture innovative pharmaceutical medicines, vaccines, and consumer healthcare products. They aim to bring, high-quality, differentiated and healthcare products that are needed to people, with their three global businesses, scientific and technical know-how, and talented people.

Product Portfolio: The company aims to bring high-quality, differentiated and needed healthcare products to many people, with their three global businesses, scientific, technical know-how, and talented people.

Key Development: On 6th August 2020, GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) had approved BLENREP (belantamab mafodotin-blmf). It is a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Key Development: Bayer adds menopause drugs to the pipeline with KaNDy acquisition. At the onset of the year, KaNDy completed a phase 2b trial of its first-in-class drug NT-814, showing activity against symptoms of menopause such as hot flashes and night sweats. A phase 3 trial is expected to have begun in 2021, and the company believes that the compound could generate peak sales of more than a billion euros globally.

Why Purchase the Report?

  • Visualize the composition of the Frozen Shoulder Syndrome Market Segmentation By Treatment and By End-user facility highlighting the key commercial assets and players.
  • Identify commercial opportunities in Frozen Shoulder Syndrome Market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Frozen Shoulder Syndrome Market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The Frozen Shoulder Syndrome Market report would provide an access to an approx. 52 market data table, 43 figures and 200 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Frozen Shoulder Syndrome Market- By Treatment

  • Physical therapy
  • Medication
  • Joint distension
  • Surgery
  • Others

Frozen Shoulder Syndrome Market- By End-user

  • Hospitals
  • Homecare
  • Other

Frozen Shoulder Syndrome Market- By Region

  • North America
  • Europe
  • South America
  • Asia Pacific
  • Middle East and Africa
Table of Contents
Product Code: DMMD3677

Table of Contents

1. Frozen Shoulder Syndrome Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Frozen Shoulder Syndrome Market- Market Definition and Overview

3. Frozen Shoulder Syndrome Market- Executive Summary

  • 3.1. Market Snippet By Treatment
  • 3.2. Market Snippet By End-user

4. Frozen Shoulder Syndrome Market-Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increased incidences of frozen shoulder will drive the market
      • 4.1.1.2. The high prevalence of diabetes and cardiovascular diseases may increase the risk of developing frozen shoulder
    • 4.1.2. Restraints:
      • 4.1.2.1. High treatment cost will hamper the market
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Frozen Shoulder Syndrome Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Reimbursement Analysis
  • 5.7. Unmet Needs

6. Frozen Shoulder Syndrome Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Frozen Shoulder Syndrome Market- By Treatment

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Segment
    • 7.1.2. Market Attractiveness Index, By Treatment Segment
  • 7.2. Physical therapy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Medication
  • 7.4. Joint distension
  • 7.5. Surgery
  • 7.6. Others

8. Frozen Shoulder Syndrome Market- By End-user

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user Segment
    • 8.1.2. Market Attractiveness Index, By End-user Segment
  • 8.2. Hospitals *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Other
  • 8.4. Homecare

9. Frozen Shoulder Syndrome Market- By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

10. Frozen Shoulder Syndrome Market- Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Benchmarking
  • 10.4. List of Key Companies to Watch
  • 10.5. List of Company with disruptive technology
  • 10.6. List of Start Up Companies

11. Frozen Shoulder Syndrome Market- Company Profiles

  • 11.1. GlaxoSmithKline plc*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Contract Pharmacal Corp
  • 11.3. Amneal Pharmaceuticals, Inc.
  • 11.4. Vintage Pharma
  • 11.5. Dr. Reddy's Laboratories Ltd
  • 11.6. Emcure Pharmaceuticals Ltd
  • 11.7. Marksans Pharma
  • 11.8. Shanghai Pharmaceutical Group Co. Ltd.
  • 11.9. China Resources Pharmaceutical GroupCo., Ltd.
  • 11.10. Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.

LIST NOT EXHAUSTIVE

12. Frozen Shoulder Syndrome Market- DataM

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us